NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC

NexTel Medical Corp. said it has executed a definitive Letter of Intent (LOI) to acquire 100% of Xycota Biosciences, LLC, a preclinical biotechnology company focused on precision-targeted therapeutics aimed at physically repairing brain circuitry. The deal announcement, dated August 5, 2026, comes as Xycota advances XYCO-01, described as using fungal-derived exosome delivery systems to upregulate the BDNF-TrkB neuroplasticity pathway while bypassing first-pass liver metabolism and avoiding hallucinogenic receptor activation. Xycota has applied to the FDA for Orphan Drug Designation for XYCO-01 in frontotemporal dementia (FTD), with issuance expected shortly; the article notes seven years of U.S. market exclusivity, tax credits, and fee exemptions if granted. Xycota’s scientific platform cites peer-reviewed mechanistic evidence in Neuropsychopharmacology and is led by Dr. Marvin S. Hausman.